Detalles de la búsqueda
1.
Attenuated cell cycle and DNA damage response transcriptome signatures and overrepresented cell adhesion processes imply accelerated progression in patients with lower-risk myelodysplastic neoplasms.
Int J Cancer
; 154(9): 1652-1668, 2024 May 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-38180088
2.
RUNX1 mutations contribute to the progression of MDS due to disruption of antitumor cellular defense: a study on patients with lower-risk MDS.
Leukemia
; 36(7): 1898-1906, 2022 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-35505182
3.
Real-world study of children and young adults with myeloproliferative neoplasms: identifying risks and unmet needs.
Blood Adv
; 6(17): 5171-5183, 2022 09 13.
Artículo
en Inglés
| MEDLINE | ID: mdl-35802458
4.
TP53 mutation variant allele frequency is a potential predictor for clinical outcome of patients with lower-risk myelodysplastic syndromes.
Oncotarget
; 7(24): 36266-36279, 2016 Jun 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-27167113
Resultados
1 -
4
de 4
1
Próxima >
>>